Related Experiment Video
Updated: Feb 6, 2026

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma
Sophie C Cheshire1, Ruth E Board1, Alexandra R Lewis1
1From the Departments of Radiology (S.C.C., M.J.D.), Oncology (R.E.B., A.R.L.), and Cellular Pathology (L.D.G.), Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Sharoe Green Lane North, Fulwood, Preston, PR2 9HT, England.
Abstract:
Pembrolizumab is a programmed cell death protein 1, or PD-1, inhibitor therapy immunotherapy for patients with advanced melanoma. This report discusses a series of documented cases of sarcoid-like reactions associated with this therapy. Three patients with malignant melanoma developed metastatic disease and were treated with pembrolizumab immunotherapy. Subsequent imaging showed lymphadenopathy in the mediastinum and hilar regions that was confirmed to represent a sarcoid-like reaction at histologic examination. Radiologists should be aware of the association between pembrolizumab and the development of sarcoid-like reactions to avoid inaccurately ascribing these imaging findings to metastatic disease. Clinical presentation, biopsy, radiographic evidence of bilateral hilar lymphadenopathy (with paratracheal lymphadenopathy), and elevated serum angiotensin-converting enzyme levels aid in the diagnosis of sarcoid-like reactions and help avoid these reactions being mistaken for recurrent or metastatic disease.
Insights
Pembrolizumab immunotherapy can cause sarcoid-like reactions in melanoma patients. Awareness of this association is crucial for accurate diagnosis, distinguishing it from metastatic disease.
Area of Science:
- Oncology
- Immunology
- Radiology
Background:
- Pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, is an immunotherapy used for advanced melanoma.
- Malignant melanoma treatment often involves complex immunotherapies with potential side effects.
Observation:
- Three patients with metastatic melanoma treated with pembrolizumab developed mediastinal and hilar lymphadenopathy.
- Histologic examination confirmed these findings represented a sarcoid-like reaction, not metastatic disease.
Findings:
- Pembrolizumab therapy is associated with the development of sarcoid-like reactions.
- Radiographic findings of lymphadenopathy can mimic metastatic disease.
Implications:
- Radiologists and clinicians must recognize this association to avoid misdiagnosis.
- Diagnosis involves clinical presentation, biopsy, imaging (bilateral hilar lymphadenopathy), and elevated angiotensin-converting enzyme levels.
- Proper diagnosis prevents unnecessary treatment escalation or changes in oncologic management.
Related Concept Videos
Allergic Reactions
Reaction Mechanisms
For instance, the decomposition of ozone appears to follow a mechanism with two steps:
Determining Order of Reaction
Reaction Yield
Reaction Rate
The mathematical representation of the change in the concentration of reactants and products, over time, is the rate...
Reaction Quotient

